Twist Bioscience Corporation Overview
Pro stress-test →Twist Bioscience is a leader in synthetic biology with a proprietary semiconductor-based DNA synthesis platform that produces high-quality synthetic DNA at faster rates and more affordably than traditional methods, serving applications in therapeutics, diagnostics, and academic research. The company is experiencing substantial AI-driven demand growth, with AI expected to become a primary step in drug discovery, reducing time and cost compared to traditional methods.
Strategic Profile
Pro stress-test →The company's ability to write DNA on silicon chips combined with proprietary software and e-commerce platform creates a highly scalable manufacturing process with significant cost advantages. Twist is targeting adjusted EBITDA breakeven by Q4 fiscal 2026 while driving toward sustained and profitable growth.
Competitive Landscape
Pro stress-test →Twist Bioscience has established itself as a leader in synthetic biology through its proprietary semiconductor-based DNA synthesis platform that produces DNA at faster rates and lower costs, giving it competitive advantage in the synthetic biology market. Key competitors include Ginkgo Bioworks and Synthego in synthetic biology, and larger players like Illumina in DNA sequencing.
Industry Context
Twist Bioscience Corporation operates in Synthetic Biology / Biotech Tools & Services.
Key facts
Founded: 2013 · Headquarters: South San Francisco, United States · Revenue: $103.7M (Q1 FY2026)